CHF2.885 close: Relief Therapeutics RLF.SW (SIX) bounce before earnings Mar 2026

RLF.SW stock closed at CHF2.885 on 17 Mar 2026 after a modest intraday gain, setting up a classic oversold bounce in the biotech name. Relief Therapeutics Holding AG (RLF.SW) on the SIX exchange traded 66,704.00 shares today, above its 50-day average and showing relative volume 1.62, a sign of renewed buying interest. The company still posts negative EPS -1.36 and a negative PE -2.12, but liquidity metrics and an upcoming earnings date on 08 Apr 2026 make the current pullback a near-term trading setup. We assess valuation, catalysts, and Meyka AI forecasts to frame a pragmatic oversold-bounce strategy for traders and investors.

RLF.SW stock: price action and volume signals

Relief Therapeutics (RLF.SW) closed at CHF2.885 with a daily range CHF2.80–CHF3.00 and volume 66,704.00, above its average volume 41,210.00. The higher-than-average volume and a positive intraday change +0.87% suggest an attempt to reverse a recent pullback. The 50-day average is CHF2.91 and the 200-day average is CHF2.61, which places today’s price near a short-term support zone.

Valuation and fundamentals for Relief Therapeutics (RLF.SW)

Relief Therapeutics tracks as a clinical-stage biotechnology company on SIX with market cap CHF36,280,179.00 and 12,575,452 shares outstanding. Key ratios show EPS -1.36, PE -2.12, price-to-book 1.11, cash per share CHF0.996, and current ratio 4.05, indicating a strong liquidity buffer despite negative earnings. Revenue per share is low at CHF0.32, and R&D spend remains material at roughly 29.70% of revenue, reflecting the pipeline development focus.

Technical setup: oversold bounce setup for RLF.SW stock

Price sits close to the 50-day moving average and above the 200-day average, a neutral-to-constructive technical posture for a bounce trade. While standard momentum indicators are incomplete in our feed, the volume uptick and a three-month gain of 7.25% suggest short-term buyers are regaining control. Traders should look for a follow-through session above CHF3.00 to confirm the bounce and manage risk with a stop near the recent low CHF1.65.

Catalysts, risks and sector context

The next earnings/announcement is scheduled for 08 Apr 2026, which can act as a catalyst for clinical updates or financial guidance. Relief operates in the Healthcare/Biotechnology sector, where average PB is 4.84 and average PE is 29.21, making RLF.SW relatively cheaper on book value but riskier on earnings. Key risks include trial setbacks, dilution from capital raises, and continued operating losses; opportunities center on positive trial data or regulatory progress for lead assets like RLF-100.

Meyka AI grade and forecast for RLF.SW

Meyka AI rates RLF.SW with a score of 64.76 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects 1‑year CHF1.73 (implied -40.09% vs CHF2.885), 3‑year CHF3.18 (implied +10.26%), and 5‑year CHF4.86 (implied +68.44%). Forecasts are model-based projections and not guarantees.

Trading strategy and realistic price targets

For an oversold-bounce trade, a short-term target near CHF3.50 and a conservative hold target at CHF4.50 align with the stock’s 52-week high CHF4.59 and Meyka forecasts. Position sizing should account for high volatility and negative earnings, with a stop loss between CHF2.20 and CHF2.50 depending on risk tolerance. Investors focused on fundamentals may prefer waiting for clearer clinical or earnings progress before adding exposure.

Final Thoughts

RLF.SW stock is trading at CHF2.885 on the SIX exchange on 17 Mar 2026 and shows a near-term oversold-bounce setup driven by above-average volume 66,704.00 and price action around the 50-day average CHF2.91. The company’s balance sheet reads better than many peers, with cash per share CHF0.996 and a current ratio 4.05, but losses persist (EPS -1.36). Meyka AI’s model projects CHF1.73 in one year (implying -40.09%) and CHF3.18 in three years (implying +10.26%) versus today’s price; these figures highlight a split risk-reward between short-term trade and longer-term recovery. For traders, confirm the bounce with a move above CHF3.00 and control size given biotech volatility. For investors, watch the 08 Apr 2026 earnings/catalyst and trial updates before increasing exposure. Remember, Meyka AI provides data-driven analysis but not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.